Arnold Hanish Sells 5,000 Shares of Omeros (NASDAQ:OMER) Stock

Omeros Corporation (NASDAQ:OMER) Director Arnold Hanish sold 5,000 shares of the business’s stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $18.53, for a total transaction of $92,650.00. Following the completion of the sale, the director directly owned 5,000 shares of the company’s stock, valued at approximately $92,650. The trade was a 50.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Omeros Stock Performance

NASDAQ:OMER traded down $0.67 during mid-day trading on Friday, reaching $18.58. 1,143,548 shares of the company’s stock were exchanged, compared to its average volume of 1,711,871. Omeros Corporation has a one year low of $3.94 and a one year high of $19.65. The business’s fifty day simple moving average is $12.48 and its two-hundred day simple moving average is $11.98. The firm has a market capitalization of $1.35 billion, a PE ratio of 14.52 and a beta of 2.54.

Omeros (NASDAQ:OMER) last posted its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.29. The business had revenue of $28.53 million during the quarter, compared to the consensus estimate of $12.69 million. As a group, equities research analysts forecast that Omeros Corporation will post -0.37 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on OMER shares. Zacks Research cut Omeros from a “strong-buy” rating to a “hold” rating in a report on Monday, July 13th. Weiss Ratings raised Omeros from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, August 5th. Wall Street Zen raised shares of Omeros from a “hold” rating to a “buy” rating in a research report on Saturday, August 15th. Finally, HC Wainwright reissued a “buy” rating on shares of Omeros in a report on Monday, July 27th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, Omeros has an average rating of “Moderate Buy” and a consensus price target of $38.00.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. acquired a new position in Omeros during the second quarter worth about $57,484,000. Vanguard Group Inc. increased its position in Omeros by 19.9% during the 4th quarter. Vanguard Group Inc. now owns 4,013,315 shares of the biopharmaceutical company’s stock worth $68,929,000 after purchasing an additional 666,357 shares in the last quarter. UBS Group AG lifted its stake in Omeros by 213.5% in the 4th quarter. UBS Group AG now owns 2,222,982 shares of the biopharmaceutical company’s stock valued at $38,180,000 after purchasing an additional 1,513,893 shares during the last quarter. Geode Capital Management LLC boosted its position in Omeros by 6.3% in the fourth quarter. Geode Capital Management LLC now owns 1,631,350 shares of the biopharmaceutical company’s stock valued at $28,026,000 after buying an additional 95,979 shares in the last quarter. Finally, State Street Corp grew its stake in shares of Omeros by 26.9% during the fourth quarter. State Street Corp now owns 1,573,526 shares of the biopharmaceutical company’s stock worth $27,025,000 after buying an additional 333,798 shares during the last quarter. Institutional investors own 48.79% of the company’s stock.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.